BioXcel Therapeutics Inc
NASDAQ:BTAI
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
US |
BioXcel Therapeutics Inc
NASDAQ:BTAI
|
63.8m USD | -0.6 | ||
US |
Abbvie Inc
NYSE:ABBV
|
285.4B USD | 14.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
167B USD | 30.6 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.4B USD | 30.1 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.5B USD | 25.6 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 85.6 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
84.3B USD | 10.7 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
49.1B USD | -11.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -59.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
33B USD | 29.8 | ||
KR |
Celltrion Inc
KRX:068270
|
39.6T KRW | 221 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.